Affimed (NASDAQ:AFMD) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Affimed (NASDAQ:AFMD) in a research note issued to investors on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

AFMD has been the topic of several other research reports. Wells Fargo & Company restated an “equal weight” rating and set a $0.10 price objective (down previously from $11.00) on shares of Affimed in a report on Tuesday, May 13th. Cantor Fitzgerald cut Affimed from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 14th. Leerink Partners restated a “market perform” rating and issued a $0.39 target price (down from $5.00) on shares of Affimed in a research note on Tuesday, May 13th. HC Wainwright lowered Affimed from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 14th. Finally, Leerink Partnrs lowered Affimed from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $7.90.

Affimed Price Performance

Shares of AFMD opened at $0.28 on Monday. The stock has a fifty day moving average price of $0.73 and a 200 day moving average price of $1.39. Affimed has a 12 month low of $0.07 and a 12 month high of $8.95. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.93 and a current ratio of 1.93.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Affimed stock. Intellectus Partners LLC raised its holdings in shares of Affimed (NASDAQ:AFMD) by 34.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 126,414 shares of the biopharmaceutical company’s stock after buying an additional 32,053 shares during the quarter. Intellectus Partners LLC owned about 0.79% of Affimed worth $150,000 as of its most recent filing with the Securities & Exchange Commission. 30.82% of the stock is currently owned by institutional investors and hedge funds.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.